In the adrenaline-fueled trajectory of an early-stage biotech, the focus is almost always on the “three pillars” of survival: clinical data, fundraising, and intellectual property. Quality Assurance (QA) is frequently treated as a fourth, distant pillar—a “check-the-box” requirement that can be deferred until a lead candidate approaches the clinic.
This is the first, and perhaps most expensive, mistake a founder can make.
Building a quality function from scratch isn’t about hiring a “policeman” to sign off on documents; it is about building the regulatory and operational skeletal system of the company. When early-stage biotechs get QA hiring wrong, they don’t just face administrative headaches; they face “value leakage” that can delay IND filings, sink partnerships, and complicate CMC (Chemistry, Manufacturing, and Controls) transitions.
Here is a breakdown of what early-stage biotechs consistently get wrong about QA hiring and how to build a function that accelerates growth rather than hindering it.
1. The “Generalist” Trap: Hiring for Title Over Stage
The most common error is hiring a “VP of Quality” from a Big Pharma background as the first QA employee. On paper, the pedigree is flawless. In practice, it is often a cultural mismatch.
Big Pharma QA leaders are used to operating within mature, highly segmented ecosystems. They have departments for document control, departments for validation, and departments for vendor audits. When dropped into a 15-person biotech, these leaders often struggle to “roll up their sleeves.” They may know what a perfect Quality Management System (QMS) looks like, but they might not know how to build one using only a shared drive and a limited budget.
The Fix: Your first QA hire needs to be a “Builder-Operator.” Look for someone who has lived through the transition from pre-clinical to Phase I. This person needs to be comfortable wearing multiple hats—writing the SOPs in the morning and auditing a CDMO in the afternoon.
2. Confusing “Compliance” with “Quality Culture”
Many CEOs hire for QA because they want to stay out of trouble with the FDA. This leads to hiring “Compliance Officers”—individuals focused solely on the “shalls” and “musts” of the CFR (Code of Federal Regulations).
While compliance is the floor, Quality is the ceiling.
In a startup, a rigid, compliance-only mindset creates a culture of “No.” This slows down R&D and creates friction between the lab and the office. If the QA function is viewed as a hurdle to be cleared, scientists will find ways to bypass it, leading to the very data integrity risks the company was trying to avoid.
The Fix: Hire a leader who views Quality as a business enabler. Look for candidates who talk about “risk-based approaches.” A good early-stage QA lead knows that a GLP-like environment for early discovery is overkill, but they also know exactly where the line is drawn when data starts supporting an IND.
3. Underestimating the “CDMO Governance” Skill Set
Most early-stage biotechs are virtual or semi-virtual, meaning their “Quality” lives at their Contract Development and Manufacturing Organization (CDMO). A common misconception is that if the CDMO is high-quality, the sponsor doesn’t need a robust internal QA function.
Regulators disagree. The FDA holds the Sponsor accountable for the product, regardless of who manufactured it.
Many biotechs hire QA people who are great at internal auditing but have never managed a high-stakes relationship with a third party. They fail to “audit the auditor” or recognize when a CDMO’s quality system is misaligned with the sponsor’s clinical timelines.
The Fix: Prioritize candidates with External Quality experience. Your first QA hire must be able to navigate Quality Agreements, manage remote deviations, and pressure-test a CDMO’s investigations without being physically on-site every day.
4. Waiting Too Late to Hire “QA Operations”
There is a tendency to hire a “Head of Quality” and stop there. However, as soon as a company moves toward GMP (Good Manufacturing Practice) materials, the bottleneck shifts from strategy to velocity.
This is where “QA Operations” comes in. If you have a Head of Quality but no one to perform the daily “grind” of batch record review and change control management, your senior leader becomes a high-priced administrator. This leads to burnout and, more importantly, delays in releasing clinical supplies.
The Fix: Budget for a “Quality Operations” specialist or manager shortly after your first senior hire. This ensures that your leadership can focus on the regulatory roadmap while your operations keep the “factory” (or the CDMO interface) moving.
5. The Digital Blind Spot
In 2026, building a paper-based QMS is a strategic liability. Yet, many early-stage biotechs hire QA leaders who are “old school” and prefer binders to Bytes.
A paper-based system is difficult to scale, impossible to search during an audit, and a nightmare for remote teams. If you hire a QA lead who isn’t “tech-forward,” you are effectively building technical debt that will cost hundreds of thousands of dollars to remediate later.
The Fix: Screen for digital literacy. Your QA lead should be able to lead the implementation of an eQMS (electronic Quality Management System) early on. A digital-first quality function makes the company much more attractive to potential acquirers or partners during due diligence.
The “Ideal” QA Hiring Roadmap
To avoid these pitfalls, consider this three-phase approach to building your quality function:
- Phase 1 (Pre-IND): Hire a Director/Senior Director of Quality who is a generalist. Their goal: Build a “right-sized” QMS and ensure data integrity in the studies supporting the IND.
- Phase 2 (Phase I/II): Hire a QA Operations/CMC Quality Manager. Their goal: Manage the CDMO relationship, handle batch releases, and manage the growing volume of deviations and change controls.
- Phase 3 (Late-Stage/Commercial): Bring in the VP/SVP of Quality. Their goal: Prepare the organization for a PAI (Pre-Approval Inspection) and ensure the systems are robust enough for commercial scale.
Conclusion: Quality as a Strategic Asset
In biotech, the “product” is the data. If the quality of that data is called into question, the value of the company evaporates.
Building a quality function is not about adding bureaucracy; it is about protecting the integrity of your science. By avoiding the Big Pharma generalist trap and hiring “builders” who understand the nuances of external manufacturing and digital systems, early-stage biotechs can turn QA from a cost center into a strategic differentiator.
The goal isn’t just to be “compliant”—it’s to be “inspection-ready” from day one.
https://shorturl.fm/fmjAZ